ArcticZymes Technologies ASA
B4V
Company Profile
Business description
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
Contact
Sykehusveien 23
Tromso9294
NORT: +47 77648900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,144.70 | 60.50 | -0.66% |
| CAC 40 | 8,139.00 | 66.37 | -0.81% |
| DAX 40 | 25,820.36 | 504.65 | -1.92% |
| Dow JONES (US) | 51,285.73 | 237.33 | -0.46% |
| FTSE 100 | 10,673.94 | 108.72 | -1.01% |
| HKSE | 24,481.86 | 315.12 | -1.27% |
| NASDAQ | 24,579.43 | 264.43 | 1.09% |
| Nikkei 225 | 57,434.77 | 3,643.13 | -5.96% |
| NZX 50 Index | 13,998.50 | 92.47 | -0.66% |
| S&P 500 | 7,376.86 | 23.13 | 0.31% |
| S&P/ASX 200 | 9,020.80 | 44.30 | -0.49% |
| SSE Composite Index | 3,649.18 | 40.73 | -1.10% |